Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database

• DOI: 10.2337/figshare.19119302.v1
• Publication Date: 2022-02-24T18:29:37Z
• Authors: Rachel Wong; Margaret Hall; Rohith Vaddavalli; Adit Anand; Neha Arora; Carolyn T. Bramante; Victor Garcia; Steven Johnson; Mary Saltz; Jena S. Tronieri; Yun Jae Yoo; John B. Buse; Joel Saltz; Joshua Miller; Richard Moffitt
• Keywords: 03 medical and health sciences; Endocrinology; 0302 clinical medicine; and Metabolism; Nutritional and Metabolic Diseases; Virus Diseases; Diabetes; Infectious Disease; UMCCTS funding; Endocrine System Diseases; 3. Good health

<i>Objective: </i>The purpose of the study is to evaluate relationship between HbA1c and severity COVID-19 outcomes in patients with type 2 diabetes mellitus (T2D) acute infection. <p><i>Research Design Methods: </i>We conducted a retrospective using observational data from National COVID Cohort Collaborative (N3C), longitudinal, multicenter US cohort Patients were ≥18 years old T2D confirmed infection by either laboratory testing or diagnosis code. The primary outcome was 30-day mortality following date diagnosis. Secondary included need for invasive ventilation ECMO, hospitalization within 7 days prior 30 after diagnosis, length stay (LOS) who hospitalized.</p> <p><i>Results: 39,616 (50.9% female, 55.4% White, 26.4% Black African American 16.1% Hispanic Latino, mean [SD] age 62.1 [13.9] 7.6% [2.0]. There an increasing risk incrementally higher levels, but death plateaued at above 8% ECMO 9%. no significant difference LOS across levels. </p> <p><i>Conclusions: </i>In large, infection, increased Risk also different levels glycemic control.</p>